HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 1053-1056

  Theys, K ^a   Vercauteren, J ^a,b   Snoeck, J ^c,d,e,f   Zazzi, M ^g   Camacho, R J ^h   Torti, C ^f,i   Schulter E ^j   Clotet, B ^k   Sonnerborg A ^l   De Luca, A ^m   Grossman, Z ⁿ   Struck, D ^a   Vandamme, A M ^b,c   Abecasise, A B ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF SIENA   (Italy)

^e Centro Hospitalar de Lisboa Ocidental   (Portugal)

^f INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^g UNIVERSITY OF BRESCIA   (Italy)

^h UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k KAROLINSKA INSTITUTE   (Sweden)

^l CATHOLIC UNIVERSITY   (Italy)

^m TEL AVIV UNIVERSITY   (Israel)

ⁿ LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; FEMALE; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MUTATION; PREVALENCE; PRIORITY JOURNAL;

ADENINE; ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

EID: 84872861293     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01668-12     Document Type: Article

References (12)

1. Camacho R, Vandamme AM. 2007. Antiretroviral resistance in different HIV-1 subtypes: Impact on therapy outcomes and resistance testing interpretation. Curr. Opin. HIV AIDS 2:123-129.
2. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, de Ruiter A, Tatt ID, Geretti AM, Zuckerman M. 2010. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J. Int. AIDS Soc. 13:4.
3. Brenner BG, Coutsinos D. 2009. The K65R mutation in HIV-1 reverse transcriptase: Genetic barriers, resistance profile and clinical implications. HIV Ther. 3:583-594.
4. Gupta RK, Chrystie IL, O'Shea S, Mullen JE, Kulasegaram R, Tong CY. 2005. K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 19:1916-1919.
5. Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, Moosa MY, Ordonez C, Kuritzkes DR, Marconi VC. 2012. High rate of K65R for ART naive patients with subtype C HIV infection failing a TDFcontaining first-line regimen in South Africa. AIDS 26:1679-1684.
6. Miller MD, Nicolas N, McColl D, Cheng AK. 2007. K65R development among subtype C HIV-1 infected in tenofovir DF clinical trials. AIDS 21:265-266.
7. von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Rickenbach M, Ledergerber B, Günthard HF, Swiss HIV Cohort Study. 2008. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin. Infect. Dis. 46:1299-1309.
8. Theys K, Vercauteren J, Abecasis AB, Libin P, Deforche K, Vandamme AM, Camacho R. 2009. The rise and fall of K65R in a Portuguese HIV-1 drug resistance database, despite continously increasing use of tenofovir. Infect. Genet. Evol. 9:683-688.
9. Waters L, Nelson M, Mandalia S, Bower M, Powles T, Gazzard B, Stebbing J. 2008. The risks and incidence of K65R and L74V mutations and subsequent virologic responses. Clin. Infect. Dis. 46:96-100.
10. Theys K, Snoeck J, Vercauteren J, Abecasis AB, Vandamme AM, Camacho RJ. 30 September 2012. Decreasing population selection rates of resistance mutation K65R over time in HIV-1 combination therapy, including tenofovir. J. Antimicrob. Chemother. [Epub ahead of print.] doi: 10.1093/jac/dks380.
11. R Development Core Team. 2011. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
12. Torti C, Quiros-Roldon E, Regazzi M, Antinori A, Patroni A, Villani P, Tirelli V, Cologni G, Zinzi D, Lo Caputo S, Perini P, Carosi G, KARINA-SISTHER Collaboration Group of the Cohort MASTER. 2005. Early virological failure after tenofovir ? didanosine ? efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir. Ther. 10:505-513.